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Quality of life (QOL) was evaluated in bitches with mammary tumours 
(MTs) by applying a scale to assess QOL in dogs with pain secondary to cancer. 
Two groups were constituted: Group 1 with 80 bitches with MT, oncologically 
classified as stage I (mean age ± SD = 9.9 ± 3.8 years), and Group 2 consisting of 
80 healthy bitches without MT (mean age: 7.7 ± 1.8 years). The results were 
based on responses from owners using a standardised, internationally accepted 
pain-scale questionnaire. This prospective and descriptive study showed that 63% 
of the dogs in Group 1 had a change in QOL due to the presence of MT. The risk 
of QOL impairment was 2.1 times higher in Group 1 animals than in bitches 
without MT. Mammary tumour increased the presence of pain 8.3 times and defe-
cation difficulties 10 times. It can be concluded that even small MTs can elicit 
pain in dogs, which interferes with their quality of life.  
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Mammary tumours (MTs) are the most common type of tumour in intact 
female dogs. The clinical presentation of canine MTs is variable; they occur ei-
ther as single or multiple nodules, ranging from well-circumscribed nodules with 
stationary growth to large and sometimes ulcerated nodules which grow rapidly 
and become fixed to adjacent tissues or display other signs of malignancy (Lana 
et al., 2007). Early surgical removal is recommended for canine MT (Lana et al., 
2007), but the veterinary practice indicates that because of the apparent absence 
of pain or the lack of sufficient commitment, many owners and even veterinari-
ans postpone surgical treatment of MT, thus compromising disease outcomes and 
the patients’ quality of life (QOL). 
The difficulty in assessing pain in animals has been a limiting factor to 
their identification and treatment. For this reason, the American College of Vet-
erinary Anesthesiologists (ACVA) established that a stimulus considered painful 
in human beings should also be considered painful in animals and the inability to 
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verbalise at no time should be interpreted as absence of pain sensation (ACVA, 
1998). The availability of quantitative measures of chronic pain that are valid 
and reliable in clinical patients is crucial for the development and testing of in-
terventions (e.g. drugs or surgical procedures) designed to reduce such pain. A 
detailed behaviour-based assessment of chronic pain performed by the owner is 
routinely relied on when making clinical decisions. This offers the advantage of 
an extended assessment of a dog in its typical environment by someone who is 
most knowledgeable about its behaviour. Although an owner’s detailed assess-
ment can be quite useful, few programmes have reported the development of an 
owner-completed questionnaire for use as an outcome assessment tool in clinical 
studies. The impact of pain associated with chronic diseases on QOL has been 
evaluated in dogs (Wiseman-Orr et al., 2004, 2006). In this study, we used the 
QOL assessment questionnaire developed by Yazbek and Fantoni (2005) be-
cause it is a questionnaire validated for pain secondary to cancer. 
In humans, cancer pain affects 50% of patients throughout the course of 
the disease. When evaluating only patients in the advanced stage, the incidence 
of pain can reach 75% (Sakata, 2004). In many types of canine cancer, however, 
the presence of pain has not been assessed. In cancer, pain may result from a va-
riety of causes: it may be caused by the tumour itself, by metastasis or by para-
neoplastic syndromes, and it can be the result of chemotherapy and radiotherapy 
(Lester and Gaynor, 2000; Teixeira, 2003). Quality of life assessments are con-
sidered to be among the principal endpoints in human clinical trials (Freeman et 
al., 2005) and are now commonplace in primary care practice (Mellanby et al., 
2003). Only in the recent decade has QOL been extensively studied and meas-
ured in companion animal medicine (Brown et al., 2008). Few studies reveal the 
true associations between tumours observed in humans and dogs, because as-
sessment of the QOL life in pets is rarely used in clinical studies. There is a con-
sensus that QOL in pets should be more broadly defined as states of comfort or 
discomfort representing a combination of physical and non-physical factors 
(McMillan, 2000; Mellanby et al., 2003). For this reason, the aim of this study 
was to evaluate whether the presence of mammary nodules can affect the QOL of 
dogs, and thus to estimate the degree of morbidity in such cases. 
 
 
Materials and methods 
Two groups were constituted: Group 1 (G1-MT) comprising 80 bitches 
with MT and Group 2 (G2-C) consisting of 80 bitches without MT. Bitches of 
Group G1-MT had only one non-ulcerated mammary tumour 1–3 cm in diame-
ter, and according to the World Health Organization Clinical Staging System (the 
TNM system) all animals were classified as T1 (< 3 cm maximum diameter), N0 
(lymph nodes not compromised by metastases) and M0 (no distant metastasis) 
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(Philbert et al., 2003). Exclusion criteria for this group were tumours larger than 
4 cm, ulcerated, recurrent tumours, animals undergoing chemotherapy or sur-
gery, presence of other tumours, and other concomitant diseases. The age of 
these dogs ranged from 5 to 19 years (mean age ± SD = 9.9 ± 3.8 years) and the 
body weight median was 15.4 ± 10.2 kg. The breeds represented in this group 
were crossbreed dogs (n = 29), standard Poodle (n = 17), Rottweiler (n = 11), Pit 
Bull (n = 8), Labrador (n = 7), Boxer (n = 2), Pinscher (n = 2), German Shepherd 
Dog (n = 2), Bull Terrier (n = 1), and Cocker Spaniel (n = 1). The diagnosis of 
mammary neoplasm was done by histopathological examination of excisional 
biopsy samples after surgical treatment (Misdorp et al., 1999). 
Group G2-C group consisted of healthy, non-neutered bitches without MT, 
aged 5 to 16 years (mean 7.7 ± 1.8 years) and with a body weight median of 13.5 ± 
11.9 kg. The major breeds belonging to Group 2 were crossbreeds (n = 26), stan-
dard Poodle (n = 14), Pinscher (n = 12), Labrador (n = 8), Pit Bull (n = 5), 
Dachshund (n = 5), Maltese (n = 3), Akita (n = 2), Rottweiler (n = 2), German 
Shepherd Dog (n = 2), and Chow Chow (n = 1). The exclusion criteria for this 
group were the presence of diseases including any tumours, and the dogs were 
not being subjected to any kind of treatment. 
We used the ‘Scale to assess quality of life in dogs with pain secondary to 
cancer’ validated by Yazbek and Fantoni (2005), which consists of a question-
naire of twelve questions and four possible response alternatives. Each question 
is worth 0 (zero) to 3 (three) points, with a maximum total score of 36 points; 
zero is considered the worst quality of life and 36 points the best quality. The 
questions cover information about general behaviour, interaction with owners, 
and assessment of pain, appetite, fatigue, sleep disturbances, stomach and intes-
tinal problems, defecation, and urination. 
The χ2-test was used to compare the prevalence of factors analysed by the 
survey, and differences were considered significant at P < 0.05. The results of the 
questionnaire allowed us to calculate the relative risks from the prevalences of all 
categories. All statistical analyses were performed using standard software 
(SPSS 15.0 for Windows, SPSS, Chicago, Illinois, USA). 
 
 
Results 
We found that 15% of the animals had a score 0, which is considered a to-
tally changed QOL, and 48.75% obtained temperament scores 1 and 2 which in-
dicate some episodes of alteration and slightly altered temperament, respectively. 
Thus we showed that 63.75% of bitches with MT had changes consistent with 
decreased QOL, and only 36.25% of the animals with MT had normal QOL. 
The owner questionnaire aimed at assessing QOL and pain in dogs with 
MT revealed that the risk of QOL impairment was 2.1 times higher in bitches 
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with MT than in those without MT. We observed that the risk of cancer patients 
developing changes in temperament (prevalence of increased aggression, isola-
tion and irritability in the MT group: 50%) increased 2.6 times as compared to 
the control group (prevalence of increased aggression, isolation and irritability: 
10%). Owners of dogs with MT were 8.3 times more likely to report pain than 
those of bitches without MT. Thus, pain was one of the predominant reasons for 
the occurrence of behavioural changes, and it can explain many other changes 
visibly present in bitches with MT. The presence of changes in defecation (diffi-
cult defecation, dyschezia) was 10 times more frequent in the MT group. This 
sign is often related to the presence of pain, and its frequency corroborates the 
occurrence of pain in patients with MT. This study demonstrated that the risk of 
vomiting episodes increased 3.7 times and the presence of intestinal disorders 1.8 
times in Group MT. Bitches with MT were attended to by their owners approxi-
mately 21 times more than bitches without MT, which fact reveals an insecurity 
due to pain or discomfort caused by the presence of tumours in dogs with MT 
(Table 1). 
Table 1 
Prevalence and risk analysis based on the results obtained through the pain and quality of life ques-
tionnaire for canine mammary tumour patients 
Factor 
Group 1 –  
dogs without MT 
(%) 
Group 2 –  
dogs with MT  
(%) 
Relative 
risk 
1.– Disturbing the animal’s life 18/50 (36) 62/80 (77.50)* 2.10* 
2.– Does not keep doing the same things 27/50 (54) 46/80 (57.50) 1.0 
3.– Loses hygiene habits 12/50 (24) 51/80 (63.75)* 5.0* 
4.– Behavioural changes 5/50 (10) 40/80 (50.00)* 2.6* 
5.– Presence of pain 5/50 (10) 67/80 (83.75)* 8.3* 
6.– Change of appetite 40/50 (80) 41/80 (51.25) 0.6 
7.– Displays tiredness 16/50 (32) 54/80 (67.50)* 2.0* 
8.– Shows changes in sleep 14/50 (28) 38/80 (47.50) 1.6* 
9.– Displays respiratory distress or vomiting 5/50 (10) 30/80 (37.50)* 3.7* 
10.– Presents intestinal disorders 15/50 (30) 44/80 (55.00)* 1.8* 
11.– Presence of postural changes to defecate 2/50 (4) 33/80 (41.20)* 10.2* 
12.– Increase of grace / family care 1/50 (2) 34/80 (42.50)* 21.0* 
*Results of χ2-test for two independent proportions, P < 0.05 
 
In Group G1-MT, we observed that 65% (52/80) of mammary tumours 
were malignant and 35% (28/80) were benign. Adenomas (17/28) and fibroade-
nomas (11/28) were the most prevalent benign mammary tumours. Histological 
analysis demonstrated that 52 dogs had carcinoma, including tubular carcinoma 
(27/52), papillary carcinoma (5/52), solid carcinoma (15/52), and complex carci-
noma (5/52). 
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Discussion 
The assessment of pain in animals, while often difficult, is extremely im-
portant. It is likely that the tolerance of pain by an individual animal varies 
greatly, and this is further complicated by the innate ability of dogs to mask sig-
nificant disease and pain. The most important people in the assessment process 
are the owners. The veterinarian must work closely with the owner to capture 
this information. Importantly, the veterinarian needs to capture information about 
behaviours or activities that have changed as a result of the cancer. Tumour char-
acteristics that decisively contribute to the occurrence of pain are tumour stage, 
size, presence of tumour ulceration, recurrence, and metastases. However, little is 
known about the pain caused by small, isolated mammary tumours in bitches, 
which was the main motivation behind this study. 
In the clinical practice, the presence of small mammary nodes in dogs can-
not demand much attention from the owner and the veterinarian because these 
tumours are of small size and the patient shows few clinical signs. Thus, 
wrongly, it is believed that the presence of little lumps does not interfere with the 
QOL of dogs. However, this study showed that about 63.75% of dogs with early-
stage MT had a change in their QOL, and the risk of QOL changes increased 2.1 
times in dogs with MT. 
The behavioural changes (aggression, difficulty in defecation) and the 
QOL of dogs were related to the presence of pain, because animals with MT had 
a 8.3 times higher risk of pain. The most common sign of pain is a change in be-
haviour, such as changes in personality or attitude, especially vocalisation when 
the painful region is touched, self-mutilation, changes in fur appearance and hy-
giene, as well as changes in posture and gait (Loney, 2010), which is consistent 
with what we found in this study. Many of these changes are manifested in subtle 
form and are barely noticeable during the daily routine of the affected animal. 
These small alterations in the animal’s behaviour are observed only by the own-
ers who report them when questioned on the subject. Thus, it is clear that tumour 
pain is not only present in dogs with large or ulcerated tumours but also in those 
with tumours of smaller size. In this case, defensive aggression (Horwitz and 
Neilson, 2008) is probably the most typical aggressive behavioural pattern.  
We found that the risk of vomiting episodes increased 3.7 times and the 
presence of intestinal disorders 1.8 times in dogs with MT. Gastrointestinal dis-
turbances are the main adverse effects reported in animals subjected to chemo-
therapy (Rassnick et al., 2007). In this study, no patient received any kind of 
treatment or chemotherapy. These signs are probably related to the presence of 
tumours or metastases. Horwitz and Neilson (2008) argue that excessive licking 
can also be considered a sign that the animal is seeking the attention of its own-
ers or experiences pain, itching, or anxiety disorders. Furthermore, excessive in-
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take of hairs or secretions from licking the tumour can cause gastrointestinal dis-
comfort (Duque and Valadão, 2008; Gaynor, 2008). 
According to the American College of Veterinary Anesthesiologists (ACVA, 
1998), the pain and suffering of animals are clinically important conditions that 
affect the quality of life in the short and long term. Besides the ethical considera-
tions of pain suppression, analgesic usage has many other proven benefits: it re-
duces emotional stress, inhibits the release harmful substances into the body, fa-
cilitates patient recovery, and reduces mortality and morbidity (Loney, 2010). 
Advanced cancer is known to be responsible for many pathophysiological 
changes related to pain and reduced QOL. The results of this study show that the 
presence of pain impairs QOL in bitches with mammary tumours of different 
sizes, including small ones. Thus, veterinarians must be alert for the treatment of 
pain, even in patients that apparently do not exhibit very clear clinical signs of 
pain. 
We conclude that mammary tumours decrease the quality of life in 
bitches, which is reflected in changes associated with pain including postural 
changes for defecation or urination, loss of hygiene habits, breathing difficulty, 
behavioural changes, and increased attention demand from the owner due to a 
feeling of insecurity. 
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